Lawfare in the orphan drug space
43(B)log
NOVEMBER 19, 2021
Neurelis, Inc. Aquestive Therapeutics, Inc., Neurelis was further along in the development process than Aquestive. Thus, according to Neurelis, Aquestive engaged in a ‘multi-year, anticompetitive campaign to derail the Food and Drug Administration’ (FDA) from approving Neurelis’s new drug.”
56 
Let's personalize your content